Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Apr 14:2025.04.14.648765.
doi: 10.1101/2025.04.14.648765.

Emerging Resistance to Novel β-Lactam β-Lactamase Inhibitor Combinations in Klebsiella pneumoniae bearing KPC Variants

Mase Hamza  1 , German M Traglia  2 , Lucia Maccari  3 , Sonia Gomez  3 , Maria Belen Sanz  3 , Usman Akhtar  1 , Vyanka Mezcord  1 , Jenny Escalante  1 , Alejandra Corso  3 , Cecilia Rodriguez  1   4 , Christopher R Bethel  5 , Gauri G Rao  6 , Marcelo E Tolmasky  1 , David Paterson  7 , Robert A Bonomo  5   8   9 , Fernando Pasteran  3 , Maria Soledad Ramirez  1
Affiliations

Emerging Resistance to Novel β-Lactam β-Lactamase Inhibitor Combinations in Klebsiella pneumoniae bearing KPC Variants

Mase Hamza et al. bioRxiv. .

Update in

Abstract

Background: Klebsiella pneumoniae carbapenemase (KPC) variants, predominantly KPC-2 and KPC-3, are significant global resistance mechanisms. KPC-2 and KPC-3 confer resistance to a broad range of β-lactams, including carbapenems, while remaining susceptible to ceftazidime-avibactam (CZA). Recently, new KPC variants have developed resistance to CZA through mutations, insertions, or deletions in regions such as the Ω-loop, 240-loop (237-243 aa), and 270-loop (266-275 aa). This study aimed to investigate the collateral resistance to cefiderocol (FDC) and cefepime/zidebactam (FPZ) among isolates with these mutations.

Methods: Fifteen clinical isolates of KPC-producing Klebsiella spp. were analyzed, representing 15 distinct variants. Antimicrobial susceptibility testing determined the MICs for CZA, carbapenems, FDC, FPZ, and other antibiotics. Synergy between CZA and FDC was assessed. Whole-genome sequencing (WGS) was used to identify mutations contributing to resistance.

Results: CZA resistance was confirmed in 12 of the 15 KPC variants. Collateral resistance to FDC was observed in eight isolates, with five exhibiting spontaneous resistant subpopulations. Six FDC-resistant strains had mutations in the 270-loop (266-275 aa). Collateral resistance to FPZ was seen in three KPC variants, especially those with mutations in the 270-loop (266-275 aa), though many Ω-loop and 240-loop (237-243 aa) mutants remained susceptible. WGS of FDC-resistant subpopulations revealed additional mutations in ompC, rpoC, dksA, and cirA.

Conclusions: This study demonstrates that emerging KPC variants showing resistance to CZA also exhibit resistance to FDC, with collateral resistance to FPZ observed to a lesser extent. Identifying mutations in bla KPC, cirA, and other genes is important to understand resistance mechanisms for effective therapies.

Keywords: KPC; cefiderocol; ceftazidime/avibactam; collateral resistance; zidebactam.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors declare no conflict of interest.

Figures

Figure 1:
Figure 1:
KPC variants aligned and compared against KPC-2. Protein sequences were retrieved from the CARD database and β-Lactamase Database. Aligned with MUSCLE, visualized by NCBI MSA viewer.
See this image and copyright information in PMC

References

    1. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8:460–9. - PMC - PubMed
    1. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–58, table of contents. - PMC - PubMed
    1. Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, et al. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. Antimicrob Agents Chemother. 2022;66:e0044722. - PMC - PubMed
    1. Taracila MA, Bethel CR, Hujer AM, Papp-Wallace KM, Barnes MD, Rutter JD, et al. Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC beta-Lactamase. Antimicrob Agents Chemother. 2022;66:e0212421. - PMC - PubMed
    1. Alsenani TA, Viviani SL, Papp-Wallace KM, Bonomo RA, van den Akker F. Exploring avibactam and relebactam inhibition of Klebsiella pneumoniae carbapenemase D179N variant: role of the Omega loop-held deacylation water. Antimicrob Agents Chemother. 2023;67:e0035023. - PMC - PubMed

Publication types

LinkOut - more resources